MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK

UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation

AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations

QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance

Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC

Akeso enrols first patient in global Phase III trial of cadonilimab vs nivolumab in first-line gastric cancer

Astellas doses first patient in Phase 3 lung cancer study

AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment

Insmed's ARIKAYCE sNDA granted priority review by FDA

Precigen announces FDA platform technology designation for AdenoVerse

Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer

GSK reports positive Jideytro data supporting potential first-line lung cancer use

Akeso presents positive results from registrational Phase III study of ivonescimab

Insilico Medicine doses first patient in Phase III trial of rentosertib

Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026